TY - JOUR
T1 - Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study
T2 - The Softened Water for Eczema Prevention (SOFTER) trial
AU - Jabbar-Lopez, Zarif Kadoos
AU - Flohr, Carsten
AU - Peacock, Janet Lesley
PY - 2019/8/20
Y1 - 2019/8/20
N2 - Introduction Atopic eczema affects 20% of UK children, and environmental factors are important in its aetiology.
Several observational studies suggest an increased risk of atopic eczema in children living in hard water
areas. The SOFtened watER for eczema prevention (SOFTER) pilot trial tests the feasibility of installing
domestic ion-exchange water softeners around the time of birth to reduce the risk of atopic eczema in
children with a family history of atopy. A further aim is to explore the pathophysiological mechanisms
for this in an embedded mechanistic study.
Methods and analysis Multi-centre parallel group assessor-blinded randomised controlled pilot trial. Participants are newborn
babies (n=80) living in a hard water (>250 mg/L calcium carbonate) area at risk of developing atopic
eczema because of a family history of atopy. Participants will be randomised prior to birth in a 1:1 ratio.
The intervention group will have an ion-exchange water softener installed prior to birth. The control
group will receive their usual domestic hard water supply. Follow up will be until six months of age. Data
will be collected at birth (baseline), 1, 3 and 6 months of age. The main outcome is the proportion of
eligible families screened who are willing and able to be randomised. Several secondary feasibility and
clinical endpoints will also be evaluated, alongside mechanistic outcomes. Data will be analysed on an
intention-to-treat basis. There will be no hypothesis testing for the clinical outcomes. Study acceptability
will be evaluated through semi-structured interviews.
Ethics and dissemination This study has been reviewed and given a favourable opinion by the North West – Liverpool East
Research Ethics Committee (Ref: 17/NW/0661). The results of the study will be reported at
international conferences and in peer-reviewed scientific journals. We will send participating families a
summary of the pilot trial results.
Registration details Clinicaltrials.gov: NCT03270566.
AB - Introduction Atopic eczema affects 20% of UK children, and environmental factors are important in its aetiology.
Several observational studies suggest an increased risk of atopic eczema in children living in hard water
areas. The SOFtened watER for eczema prevention (SOFTER) pilot trial tests the feasibility of installing
domestic ion-exchange water softeners around the time of birth to reduce the risk of atopic eczema in
children with a family history of atopy. A further aim is to explore the pathophysiological mechanisms
for this in an embedded mechanistic study.
Methods and analysis Multi-centre parallel group assessor-blinded randomised controlled pilot trial. Participants are newborn
babies (n=80) living in a hard water (>250 mg/L calcium carbonate) area at risk of developing atopic
eczema because of a family history of atopy. Participants will be randomised prior to birth in a 1:1 ratio.
The intervention group will have an ion-exchange water softener installed prior to birth. The control
group will receive their usual domestic hard water supply. Follow up will be until six months of age. Data
will be collected at birth (baseline), 1, 3 and 6 months of age. The main outcome is the proportion of
eligible families screened who are willing and able to be randomised. Several secondary feasibility and
clinical endpoints will also be evaluated, alongside mechanistic outcomes. Data will be analysed on an
intention-to-treat basis. There will be no hypothesis testing for the clinical outcomes. Study acceptability
will be evaluated through semi-structured interviews.
Ethics and dissemination This study has been reviewed and given a favourable opinion by the North West – Liverpool East
Research Ethics Committee (Ref: 17/NW/0661). The results of the study will be reported at
international conferences and in peer-reviewed scientific journals. We will send participating families a
summary of the pilot trial results.
Registration details Clinicaltrials.gov: NCT03270566.
KW - atopic eczema
KW - dermatology
KW - pilot trial
KW - water hardness
UR - http://www.scopus.com/inward/record.url?scp=85071273656&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2018-027168
DO - 10.1136/bmjopen-2018-027168
M3 - Article
SN - 2044-6055
VL - 9
JO - BMJ Open
JF - BMJ Open
IS - 8
M1 - e027168
ER -